Interim Chief Medical Officer
Karsten Witt, M.D., brings more than 30 years of clinical development and regulatory affairs experience in the areas of oncology and inflammatory disease. Prior to joining Black Diamond, Karsten served as Vice President, Clinical Sciences & Drug Safety at Array BioPharma, and as Senior Vice President, Pharmaceutical Operations at OSI Pharmaceuticals, where he was involved in the development of small-molecule targeted oncology therapies. He has served on executive management and global development committees, and as a chair of scientific committee for TopoTarget, a Copenhagen-based biotechnology company, until its merger with BioAlliance, which resulted in the formation of Onxeo.
Karsten earned his M.D. from the University of Copenhagen and practiced medicine at Hvidovre University Hospital in Copenhagen in the internal medicine subspecialties of gastroenterology, infectious disease, and cardiology, before transitioning to the biopharmaceutical industry.